Trial Profile
A phase 2 evaluation of oral LY317615 in patients with relapsed or refractory diffuse large B-Cell lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Aug 2020
Price :
$35
*
At a glance
- Drugs Enzastaurin (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 27 Dec 2007 The expected completion date for this trial is now 1 Jan 2009.
- 25 Sep 2005 New trial record.